Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study

• Auteurs principaux: Hong Zhang (Auteur), Min Wu (Auteur), Jixuan Sun (Auteur), Xiaoxue Zhu (Auteur), Cuiyun Li (Auteur), Yanhua Ding (Auteur), Xiaodi Zhang (Auteur), Katherine Chai (Auteur), Xiaojiao Li (Auteur)
• Format: Livre
• Publié: Wiley, 2021-04-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Abstract The primary objective of this randomized, double‐blind, parallel‐controlled study (from December 2016 to October 2018) was to evaluate pharmacokinetic (PK) equivalence of adalimumab biosimilar HLX03 and reference adalimumab in healthy volunteers, and to assess safety, and immunogenicity of...